Sugi Predict

Sugi Predict / Compounds / SCHEMBL233485

SCHEMBL233485

SCHEMBL233485

CCC(CC)OC(=O)CC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 1/20 0.37
▸ LDHA P00338 1/20 0.36
▸ SRR Q9GZT4 1/20 0.36
▸ CYP1A2 P05177 3/20 0.36
▸ MAPK1 P28482 5/20 0.35
▸ MAPT P10636 4/20 0.35
▸ LMNA P02545 4/20 0.35
▸ GMNN O75496 3/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ HSP90AA1 P07900 2/20 0.35
▸ BLM P54132 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ NR1H4 Q96RI1 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ FFAR3 O14843 1/20 0.35
▸ MME P08473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28314304 0.98 CTSK (0.36) CTSKLDHASRRCYP1A2MAPK1
SCHEMBL233484 0.87 MGAM (0.43) CTSKMAPK1MAPTLMNAMEN1
SCHEMBL1205855 0.87 PRKCA (0.42) CTSKCYP1A2MAPK1MAPTLMNA
SCHEMBL10430470 0.86 PRKCA (0.41) CTSKCYP1A2MAPK1MAPTLMNA
SCHEMBL27884310 0.84 PRKCA (0.45) CTSKCYP1A2MAPK1MAPTLMNA
SCHEMBL28615228 0.82 FAAH (0.44) CYP1A2MAPK1MAPTLMNAGMNN
SCHEMBL28608642 0.82 CTSK (0.42) CTSKCYP1A2MAPK1MAPTLMNA
SCHEMBL7321395 0.81 MGAM (0.50) CTSKMAPK1MAPTLMNAMEN1
SCHEMBL28314743 0.80 FAAH (0.42) CYP1A2MAPK1MAPTLMNAGMNN
SCHEMBL17960425 0.80 TSHR (0.34) CYP1A2MAPK1MAPTLMNAGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230223869-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION C-Motive Technologies, Inc. (US) 2023-07-13 — — US claimed
US-11601069-B2 Electrostatic machines that include a malonate in a dielectric fluid C-Motive Technologies, Inc. (US) 2023-03-07 — — US claimed
US-20210391809-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION NATIONAL SCIENCE FOUNDATION 2021-12-16 — — US claimed
US-11114951-B2 Electrostatic machine system and method of operation C-MOTIVE TECHNOLOGIES INC. (US) 2021-09-07 — — US claimed
CN-107922575-B Process for producing rigid polyurethane foams 巴斯夫欧洲公司 2021-08-17 — — CN claimed
US-20190296659-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION C-MOTIVE TECHNOLOGIES INC. (US) 2019-09-26 — — US claimed
EP-3539208-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION C-Motive Technologies Inc. (US) 2019-09-18 — — EP claimed
EP-3310835-A1 METHOD FOR PRODUCING A RIGID POLYURETHANE FOAM BASF SE (DE) 2018-04-25 — — EP claimed
US-4828764-A N-Fluoro-N-Perfluoromethyl sulfonamides RESEARCH CORPORATION (US) 1989-05-09 — — US claimed
US-12209094-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2025-01-28 — — US disclosed
US-20240109909-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2024-04-04 — — US disclosed
CN-117178030-A Aqueous coating composition for corrosion protection 湛新奥地利有限公司 2023-12-05 — — CN disclosed
US-11731981-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2023-08-22 — — US disclosed
US-20230223869-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION C-Motive Technologies, Inc. (US) 2023-07-13 — — US disclosed
EP-0211578-A2 N-fluoro-N-perfluoromethyl sulfonamides Research Corporation (US) 1987-02-25 — — EP disclosed
US-4501896-A Phenylmercaptotetrazolo- and nitroindazolo masked development/image modifiers E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-02-26 — — US disclosed
EP-0094599-A1 Use of aminophenylacetic acid derivatives for the manufacture of an immunomodulating medical preparation MITSUBISHI KASEI CORPORATION (JP) 1983-11-23 — — EP disclosed
EP-0077980-A2 (Potassium ion-selective membrane) electrode NOVA BIOMEDICAL CORPORATION (US) 1983-05-04 — — EP disclosed
US-4361473-A CROWN COMPOUNDS NOVA BIOMEDICAL CORPORATION (US) 1982-11-30 — — US disclosed
US-4343893-A RELEASED VIA ELECTRON TRANSFER E. I. DU PONT DE NEMOURS AND COMPANY (US) 1982-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210391809-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION EZH2, LAGE3, CHD4 CTSK 4221/4885LDHA 794/4885SRR 2677/4885
US-11114951-B2 Electrostatic machine system and method of operation EZH2, LAGE3, CHD4 CTSK 4221/4885LDHA 794/4885SRR 2677/4885
US-11731981-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 CTSK 1273/4885LDHA 3031/4885SRR 2845/4885
US-20240109909-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 CTSK 1273/4885LDHA 3031/4885SRR 2845/4885
US-12209094-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 CTSK 1273/4885LDHA 3031/4885SRR 2845/4885
US-20190296659-A1 ELECTROSTATIC MACHINE SYSTEM AND METHOD OF OPERATION EZH2, LAGE3, CHD4 CTSK 4221/4885LDHA 794/4885SRR 2677/4885
US-11601069-B2 Electrostatic machines that include a malonate in a dielectric fluid MAL2, SELE, LAGE3 CTSK 4112/4885LDHA 162/4885SRR 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.